Experience
About Us
中文网站
Offices
Careers
Client Advantage
Client Login
Experience
Represented Intervenor-Defendant Mylan Pharmaceuticals Inc. in a suit brought by Teva Pharmaceuticals against the FDA under the Administrative Procedure Act. Teva sought to force FDA to reclassify the multiple sclerosis drug Copaxone as a biologic product in order to frustrate generic competition. Successfully obtained summary judgment against Teva on all claims.
We use cookies on this website to enhance your user experience and to improve the quality of our site. By continuing to use this website, you are demonstrating your consent to the placement and use of cookies as described in our Cookie Policy.